Memorial Sloan Kettering Cancer Center Oncologists Co-Lead Study on KRAS-Targeted Cancer Vaccine
Memorial Sloan Kettering Cancer Center shared a post on X, about an article published on Nature Medicine:
“According to a study co-led by researchers at MSK and published in Nature Medicine, a new vaccine shows encouraging early results as a potential ready-made treatment for patients with pancreatic or colorectal cancer. Unlike individualized cancer vaccines, which are tailored to each patient, ready-made vaccines can be mass-produced and stored for immediate use.
The vaccine, ELI-002 2P, targets tumors with mutations (or changes) in the KRAS gene, a driving force in many cancers, and is given after surgery to prevent or delay a return of cancer. ‘Having this type of vaccine would make it easier, faster, and less expensive to treat a larger number of patients,’ says medical oncologist and pancreatic cancer specialist Eileen M O’Reilly, who co-led the trial. ‘This gives hope for people with pancreatic and colorectal cancer who have been out of effective treatments when their disease returns.’ “
Read more here.
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant and Eileen M. O’Reilly.
You can read the Full Article on Nature Medicine.
More posts featuring Memorial Sloan Kettering Cancer Center on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023